Merck KGaA, Darmstadt, Germany, announced the discontinuation of the randomized phase III TrilynX study evaluating xevinapant plus the chemosensitizing properties of xevinapant. The company will conduct a thorough review of the data and share the results in a peer-reviewed forum. SCCHN has proven to be a difficult form of cancer to treat.
CRT has remained the standard of care for decades, despite numerous studies aimed at improving outcomes with new therapeutic approaches, including numerous immunotherapy trials. Considering all the data, the company decided to also stop the phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy, compared to placebo plus radiotherapy) in patients who underwent resection of a locally advanced head and neck cancer. The company strives to develop and deliver new therapeutic options that exploit the vulnerabilities of tumor cells.
She is exploring modalities such as antibody-drug conjugates (ADCs) and DNA damage response (DDR) inhibitors, for multiple tumor types, including those that have proven difficult to treat and for which there are significant unmet patient needs. The Company’s support for the head and neck cancer community remains steadfast with Erbitux, which the Company markets outside of the United States and Canada. Erbitux is approved in Europe in combination with radiotherapy for the treatment of locally advanced head and neck cancer.
Erbitux continues to be studied in more than 200 active clinical trials, including at least 15 Phase III studies.
